A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling
Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.
Authors
- Sameena Nikhat (ORCID: https://orcid.org/0000-0003-1796-671X)
- Farshid Fathi (ORCID: https://orcid.org/0000-0002-0280-7612)
- Andrew Kelvin Sewell (ORCID: https://orcid.org/0000-0003-3194-3135)
- Klaus H. Kaestner (ORCID: https://orcid.org/0000-0002-1228-021X)
- Mohsen Khosravi‐Maharlooei (ORCID: https://orcid.org/0000-0002-1394-9245)
- Audrey V. Parent (ORCID: https://orcid.org/0000-0003-4506-6268)
- Austin Chen (ORCID: https://orcid.org/0000-0001-5107-2651)
- Daniel Traum (ORCID: https://orcid.org/0000-0002-0195-5525)
- Megan Sykes (ORCID: https://orcid.org/0000-0002-4947-4376)
- Edwin Bremer (ORCID: https://orcid.org/0000-0002-0325-7376)
- Mateusz Legut (ORCID: https://orcid.org/0000-0002-8810-6971)
- Giorgia Zanetti (ORCID: https://orcid.org/0000-0002-3194-0877)
- Xiaolan Ding (ORCID: https://orcid.org/0000-0001-9044-784X)
- A. C. Chen
- Rémi J. Creusot (ORCID: https://orcid.org/0000-0002-8328-8155)
- Nathan Suek (ORCID: https://orcid.org/0000-0002-0253-8950)
- Hao Wei Li (ORCID: https://orcid.org/0009-0002-2617-268X)
- Farshid Fathi
- Mohsen Khosravi Maharlooei
- Klaus Kaestner
- Nato Teteloshvili
- Ryan E. Hoang
Institutions
- Mayo Clinic (US)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- University of California, San Francisco (US)
- Columbia University Irving Medical Center (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Columbia University (US)
- Cardiff University (GB)
- University of Pennsylvania (US)
Publication Details
- Journal
- JCI Insight
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1172/jci.insight.201920
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.12
Funders
- American Diabetes Association
- Wellcome Trust
- Human Islet Research Network
- National Institutes of Health
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Research Resources